A downtrend has been apparent in Clearside Biomedical, Inc. (CLSD) lately with too much selling pressure. The stock has declined 15.7% over the past four weeks. However, given the fact that it is now in oversold territory and Wall Street analysts are majorly in agreement about the company's ability to report better earnings than they predicted earlier, the stock could be due for a turnaround. Guide to Identifying Oversold Stocks We use Relative Strength Index (RSI), one of the most commonly used technical i ...

Clearside Biomedical, Inc. (CLSD) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to loss of $0.15 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 28.57%. A quarter ago, it was expected that this company would post a loss of $0.14 per share when it actually produced a loss of $0.17, delivering a surprise of -21.43%. Over the last four quarters, the compan ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-37783 Clearside Biomedical, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 45-2437375 (State or other jurisdiction of incorporation or organiz ...

Revenue Performance - License and other revenue for Q2 2024 was $90,000, a decrease from $1.0 million in Q2 2023[5]. Expenses - Research and development expenses for Q2 2024 were $4.6 million, down from $4.9 million in Q2 2023, primarily due to reductions in the CLS-AX program and SCS Microinjector development[5]. - Total operating expenses for Q2 2024 were $7.68 million, compared to $8.29 million in Q2 2023[12]. - Non-cash interest expense remained constant at $2.3 million in both Q2 2024 and Q2 2023[5]. Financial Performance - Net loss for Q2 2024 was $7.6 million, or $0.10 per share, compared to a net loss of $9.1 million, or $0.15 per share, in Q2 2023[5]. - As of June 30, 2024, Clearside's cash, cash equivalents, and short-term investments totaled $29.4 million, expected to fund operations into Q3 2025[6]. Clinical Trials and Partnerships - Topline data from the Phase 2b ODYSSEY clinical trial of CLS-AX is expected in late Q3 2024[2]. - Clearside's Asia-Pacific partner, Arctic Vision, reported positive results from its Phase 3 trial for XIPERE, with NDAs accepted for review in Australia and Singapore[3]. - 87.7% of eyes treated with XIPERE did not require additional corticosteroid injections for 6 months after a single dose[2]. - Clearside's gene therapy partner, REGENXBIO, plans to initiate a global pivotal trial in H1 2025 for diabetic retinopathy[3].

ALPHARETTA, Ga., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced that management will present a corporate update at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference which will be available on demand on Thursday, August 15, 2024, at 7:00 a.m. ET. Victor Chong, MD, MBA, Chief Medical Officer, will also participate in a panel ...

ALPHARETTA, Ga., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that its second quarter 2024 financial results will be reported on Monday, August 12, 2024, after the close of the financial markets. In lieu of a second quarter 2024 conference call, the Company hosted a Suprachoroidal Delivery Key Opinion Leader Webinar on Wednesday ...

ALPHARETTA, Ga., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that its second quarter 2024 financial results will be reported on Monday, August 12, 2024, after the close of the financial markets. In lieu of a second quarter 2024 conference call, the Company hosted a Suprachoroidal Delivery Key Opinion Leader Webinar on Wednesday ...

Source: Clearside Biomedical, Inc. its own pipeline of small molecule product candidates for administration via its SCS Microinjector. The Company's lead program, CLS-AX (axitinib injectable suspension), for the treatment of neovascular age-related macular degeneration (wet AMD), is in Phase 2b clinical testing. Clearside developed and gained approval for its first product, XIPERE® (triamcinolone acetonide injectable suspension) for suprachoroidal use, which is available in the U.S. through a commercial par ...

Clearside Biomedical, Inc. (NASDAQ:CLSD) Suprachoroidal Space Drug Delivery Call July 24, 2024 8:00 AM ET Company Participants Jenny Kobin - Investor Relations George Lasezkay - President and Chief Executive Officer Glenn Yiu - Scientific Advisory Board Victor Chong - Chief Medical Officer David Brown - Director of Research, Retina Consultants Houston Conference Call Participants Annabel Samimy - Stifel Andreas Argyrides - Oppenheimer & Co. Serge Belanger - Needham & Company Yi Chen - H.C. Wainwright Operat ...

Core Insights - Clearside Biomedical is focused on the potential of suprachoroidal drug delivery, positioning itself as a leader in this innovative space with a proprietary SCS Microinjector that has been validated through numerous clinical injections [7][10][37] - The company has developed the first FDA-approved product for suprachoroidal administration, XIPERE, which is currently being commercialized in the U.S. and is seeking approval in Canada and Australia [12][37] - The pipeline includes CLS-AX, a tyrosine kinase inhibitor for wet AMD, which is completing Phase IIb trials, with data expected in late Q3 2024 [8][11][56] Company Overview - Clearside Biomedical has established multiple strategic collaborations to enhance its capabilities in the suprachoroidal space, including partnerships with Aura, REGENXBIO, AbbVie, and BioCryst [13][14] - The company has a comprehensive intellectual property portfolio surrounding its microinjector platform, which supports various drug categories for retinal diseases [7][10] Product Development - The SCS Microinjector has been used in over 10,000 injections without reported cases of endophthalmitis, indicating a favorable safety profile compared to traditional intravitreal injections [40] - XIPERE has shown promising real-world efficacy, with approximately 86.5% of patients not requiring rescue therapy within six months, comparable to clinical trial results [30][37] Market Potential - The market for geographic atrophy is considered larger than that for wet AMD, with ongoing research into improving treatment efficacy and duration [58] - The company aims to leverage its expertise in suprachoroidal delivery to develop therapies targeting geographic atrophy, which is increasingly recognized as a choroidal disease [62][66] Future Outlook - Clearside Biomedical plans to initiate a Phase III study for CLS-AX, which is expected to provide data that could facilitate its approval and integration into clinical practice [55][56] - The company is exploring the potential of gene therapy applications through its suprachoroidal delivery system, which may offer advantages over traditional methods [66][68]